Reference Library
The Peptide Encyclopedia
Your comprehensive guide to therapeutic peptides. Explore mechanisms, clinical evidence, FDA status, and find clinics that offer them. 110 peptides covered and growing.
Your comprehensive guide to therapeutic peptides. Explore mechanisms, clinical evidence, FDA status, and find clinics that offer them. 110 peptides covered and growing.
Showing 20 peptides in Weight Loss
GLP-1 Receptor Agonist
FDA-approved GLP-1 agonist for weight loss and type 2 diabetes.
GIP/GLP-1 Receptor Agonist
Dual GIP/GLP-1 agonist for weight loss and type 2 diabetes.
GLP-1 Receptor Agonist
FDA-approved GLP-1 receptor agonist for weight management and type 2 diabetes.
Triple Incretin Agonist
Retatrutide (LY3437943) is an investigational triple GLP-1/GIP/glucagon receptor agonist from Eli Lilly. In Phase 2 obesity trials it produced up to ~24% mean weight loss at 48 weeks — the highest reported for any obesity drug — but it is not FDA-approved and has no legal commercial source as of 2026.
Amylin Analogue
Cagrilintide is a long-acting amylin analogue in Phase 3 development, studied in combination with semaglutide (CagriSema). The CagriSema combination achieved approximately 22.7% body weight reduction at 68 weeks in the SCALE trial.
GLP-1/Glucagon Dual Agonist
Survodutide (BI 456906) is a dual GLP-1 and glucagon receptor agonist in Phase 3 trials for obesity and MASH (metabolic-associated steatohepatitis), demonstrating approximately 14.9% weight loss at 46 weeks in Phase 2b studies.
GLP-1/Glucagon Dual Agonist
Mazdutide (IBI362) is a weekly GLP-1 and glucagon receptor dual agonist developed by Innovent Biologics, currently in Phase 3 trials in China. Phase 3 GLORY-1 trial data showed 14.5% body weight reduction over 36 weeks.
Amino Acid Derivative
L-Carnitine is a conditionally essential amino acid derivative (β-hydroxy-γ-trimethylaminobutyric acid) that facilitates the transport of long-chain fatty acids across the inner mitochondrial membrane for β-oxidation, serving as a critical cofactor in energy metabolism.
Growth Hormone Releasing Hormone Analog
Tesamorelin is a synthetic research peptide and stabilized analog of growth hormone–releasing hormone (GHRH).
Peptide Blend
CagriSema, a compounded combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide, studied in Phase 3 REDEFINE trials with approximately 22.7% body weight reduction at 68 weeks.
Growth Hormone Secretagogue
A research peptide blend formulated to investigate growth hormone axis modulation through combined GHRH and ghrelin receptor pathways.
AICAR is a research compound that acts as an AMP analog activating AMP-activated protein kinase (AMPK).
O-304 is a synthetic small-molecule research compound developed to modulate cellular senescence-associated pathways.
Targeted proapoptotic compound
Adipotide, also known as FTPP, is a synthetic research peptide designed as a targeted proapoptotic compound.
Growth Hormone Fragment
AOD-9604 is a research peptide consisting of amino acids 177–191 of the human growth hormone sequence.
Peptide Blend
A triple-peptide compounded blend combining AOD-9604 (fat-mobilizing GH fragment) with CJC-1295 and ipamorelin for comprehensive GH-axis optimization with targeted lipolysis.
Peptide Blend
A compounded blend combining ipamorelin (ghrelin receptor agonist) with tesamorelin (GHRH analogue) for synergistic GH secretion with tesamorelin's additional visceral fat-reducing properties.
Triple Monoamine Reuptake Inhibitor
Tesofensine is a synthetic small-molecule research compound classified as a triple monoamine reuptake inhibitor.
Mitochondrial-Derived Peptide
MOTS-c is a mitochondrial-derived peptide composed of 16 amino acids.
5-amino-1MQ is a small-molecule research compound that functions as a selective nicotinamide N-methyltransferase (NNMT) inhibitor.